Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Celltrion Aims to Market 11 Biosimilars in Japan, Infliximab “Biobetter” in the List
Celltrion Healthcare is expanding its pipeline of biosimilars in Japan. Of its six products approved globally, two are already on the market and four more are coming along well in development. With a further five in early-stage trials, the South…
To read the full story
Related Article
- Celltrion Files Biosimilar without Japanese Clinical Data, More Firms Might Follow
October 24, 2025
- Celltrion Set for 6 Biosimilar Filings in 2 Years, Sees Japanese Data Waiver as a Boon
February 6, 2025
- Celltrion Japan Unveils New List of 5 Biosimilars in Development; Actemra and Pralia and More
May 1, 2024
BUSINESS
- Merck Biopharma Starts Japan PIII Trial of LH/FSH Combo
July 17, 2026
- Eisai’s Dayvigo Accepted for EMA Review
July 17, 2026
- AbbVie Files Maviret for Acute Hepatitis C
July 17, 2026
- FRONTEO, Santen Advance AI Drug Discovery Project to Second Phase
July 17, 2026
- Ferring’s Adstiladrin, Boehringer’s Jascayd Hit Market; Haizexin Due July 28
July 16, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…